Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma-Reference-Cited by-同舟云学术

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma

Published:2019 Issue:1 Volume:82 Page:62
ISSN:1738-3536
Container-title:Tuberculosis and Respiratory Diseases
language:en
Short-container-title:Tuberc Respir Dis

Author:

Kim Seo Yun¹^ORCID,Myung Jae Kyung²,Kim Hye-Ryoun¹,Na Im Il³,Koh Jae Soo²,Baek Hee Jong⁴,Kim Cheol Hyeon¹^ORCID

Affiliation:

1. Division of Pulmonology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

2. Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

3. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

4. Department of Thoracic Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

Funder

Ministry of Science, ICT and Future Planning

Publisher

The Korean Academy of Tuberculosis and Respiratory Diseases

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Link

https://synapse.koreamed.org/pdf/10.4046/trd.2018.0004

Reference33 articles.

1. Lung Cancer Statistics

2. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer